Skip to main content
Erschienen in: Medical Oncology 5/2023

01.05.2023 | Original Paper

The effects of KIR2DL4 stimulated NK-92 cells on the apoptotic pathways of HER2 + /HER-breast cancer cells

verfasst von: Nil Kilic, Mohammadreza Dastouri, Irfan Kandemir, Erkan Yilmaz

Erschienen in: Medical Oncology | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Natural killer (NK) cells are immune cells that have attracted significant attention due to their cytotoxic properties. They are believed to be highly effective in cancer therapy. In this study, anti-KIR2DL4 (Killer cell Immunoglobulin like Receptor, 2 Ig Domains and Long cytoplasmic tail 4) was used to stimulate the NK-92 activator receptor to increase their cytotoxicity on breast cancer cell lines. Unstimulated and stimulated NK-92 cells (sNK-92) were cocultured with breast cancer (MCF-7 and SK-BR-3) and normal breast (MCF-12A) cell lines at 1:1, 1:5, and 1:10 (Target:Effector) ratios. The most effective cell cytotoxicity ratio (1:10) was used in the immunostaining and western blot assays to evaluate apoptosis pathway proteins. The sNK-92 cells showed higher cytotoxic activity on breast cancer cells than NK-92 cells. sNK-92 cells had a selective significant cytotoxicity effect on MCF-7 and SK-BR-3 cells but not MCF-12A cells. While sNK-92 cells were effective at all cell concentrations, they were most effective at a 1:10 ratio. Immunostaining and western blots showed significantly higher BAX, caspase 3, and caspase 9 protein levels in all breast cancer cell groups cocultured with sNK-92 than with NK-92 cells. NK-92 cells stimulated with KIR2DL4 showed elevated cytotoxic activity. The cytotoxic activity of sNK-92 cells on breast cancer cells is via apoptosis pathways. However, their effect on normal breast cells is limited. While the obtained data contains only basic information, additional clinical studies are needed to provide a basis for a new treatment model.

Graphical abstract

Literatur
3.
Zurück zum Zitat Bayraktar R, Pichler M, Kanlikilicer P, et al. MicroRNA 603 acts as a tumor suppressor and inhibits triple negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget. 2017;8(7):11641.CrossRefPubMed Bayraktar R, Pichler M, Kanlikilicer P, et al. MicroRNA 603 acts as a tumor suppressor and inhibits triple negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget. 2017;8(7):11641.CrossRefPubMed
7.
Zurück zum Zitat Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687–92.CrossRefPubMed Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687–92.CrossRefPubMed
9.
Zurück zum Zitat Lesokhin AM, Callahan MK, Postow MA, Wolchok JD. On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med. 2015;7(280):280sr1-80sr1.CrossRefPubMed Lesokhin AM, Callahan MK, Postow MA, Wolchok JD. On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med. 2015;7(280):280sr1-80sr1.CrossRefPubMed
10.
Zurück zum Zitat Stojanovic A, Fiegler N, Brunner-Weinzierl M, Cerwenka A. CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-γ production in response to mature dendritic cells. J Immunol. 2014;192(9):4184–91.CrossRefPubMed Stojanovic A, Fiegler N, Brunner-Weinzierl M, Cerwenka A. CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-γ production in response to mature dendritic cells. J Immunol. 2014;192(9):4184–91.CrossRefPubMed
12.
Zurück zum Zitat Tonn T, Schwabe D, Klingemann HG, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013;15(12):1563–70.CrossRefPubMed Tonn T, Schwabe D, Klingemann HG, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013;15(12):1563–70.CrossRefPubMed
15.
Zurück zum Zitat Romagné F, André P, Spee P, et al. Preclinical characterization of 1–7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells. Blood, J Am Soc Hematol. 2009;114(13):2667–77. Romagné F, André P, Spee P, et al. Preclinical characterization of 1–7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells. Blood, J Am Soc Hematol. 2009;114(13):2667–77.
19.
Zurück zum Zitat Leung W. Infusions of allogeneic natural killer cells as cancer therapy. Clin Cancer Res. 2014;20(13):3390–400.CrossRefPubMed Leung W. Infusions of allogeneic natural killer cells as cancer therapy. Clin Cancer Res. 2014;20(13):3390–400.CrossRefPubMed
22.
Zurück zum Zitat Rajagopalan S, Fu J, Long EO. Cutting edge: induction of IFN-γ production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells. J Immunol. 2001;167(4):1877–81.CrossRefPubMed Rajagopalan S, Fu J, Long EO. Cutting edge: induction of IFN-γ production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells. J Immunol. 2001;167(4):1877–81.CrossRefPubMed
25.
Zurück zum Zitat Kataoka TR, Ueshima C, Hirata M, Minamiguchi S, Haga H. Killer immunoglobulin-like receptor 2DL4 (Cd158d) regulates human mast cells both positively and negatively: Possible roles in pregnancy and cancer metastasis. Int J Mol Sci. 2020;21(3):954.CrossRefPubMedPubMedCentral Kataoka TR, Ueshima C, Hirata M, Minamiguchi S, Haga H. Killer immunoglobulin-like receptor 2DL4 (Cd158d) regulates human mast cells both positively and negatively: Possible roles in pregnancy and cancer metastasis. Int J Mol Sci. 2020;21(3):954.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med. 2009;266(2):154–81.CrossRefPubMed Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med. 2009;266(2):154–81.CrossRefPubMed
28.
Zurück zum Zitat Khanna V, Panyam J, Griffith TS. Exploiting antibody biology for the treatment of cancer. Immunotherapy. 2020;12(4):255–67.CrossRefPubMed Khanna V, Panyam J, Griffith TS. Exploiting antibody biology for the treatment of cancer. Immunotherapy. 2020;12(4):255–67.CrossRefPubMed
29.
Zurück zum Zitat Lin W, Voskens CJ, Zhang X, et al. Fc-dependent expression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137 monoclonal antibodies. Blood, J Am Soc Hematol. 2008;112(3):699–707. Lin W, Voskens CJ, Zhang X, et al. Fc-dependent expression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137 monoclonal antibodies. Blood, J Am Soc Hematol. 2008;112(3):699–707.
30.
Zurück zum Zitat Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res. 2013;19(5):1044–53.CrossRefPubMedPubMedCentral Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res. 2013;19(5):1044–53.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Karlitepe A, Atakul T, KILIÇ Eren M (2021) Cytotoxic Effect of cord blood derived natural killer cells on breast cancer cells. Turkish J Oncol/Türk Onkoloji Dergisi 36(2). Karlitepe A, Atakul T, KILIÇ Eren M (2021) Cytotoxic Effect of cord blood derived natural killer cells on breast cancer cells. Turkish J Oncol/Türk Onkoloji Dergisi 36(2).
32.
Zurück zum Zitat Wang J, Sun Z-M, Cao L-L, Li Q. Biological characteristics of cord blood natural killer cells induced and amplified with IL-2 and IL-15. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012;20(3):731–5.PubMed Wang J, Sun Z-M, Cao L-L, Li Q. Biological characteristics of cord blood natural killer cells induced and amplified with IL-2 and IL-15. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012;20(3):731–5.PubMed
33.
Zurück zum Zitat Turaj AH, Cox KL, Penfold CA, et al. Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. Sci Rep. 2018;8(1):1–11.CrossRef Turaj AH, Cox KL, Penfold CA, et al. Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. Sci Rep. 2018;8(1):1–11.CrossRef
34.
Zurück zum Zitat Kohrt HE, Houot R, Weiskopf K, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Investig. 2012;122(3):1066–75.CrossRefPubMedPubMedCentral Kohrt HE, Houot R, Weiskopf K, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Investig. 2012;122(3):1066–75.CrossRefPubMedPubMedCentral
Metadaten
Titel
The effects of KIR2DL4 stimulated NK-92 cells on the apoptotic pathways of HER2 + /HER-breast cancer cells
verfasst von
Nil Kilic
Mohammadreza Dastouri
Irfan Kandemir
Erkan Yilmaz
Publikationsdatum
01.05.2023
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 5/2023
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-023-02009-6

Weitere Artikel der Ausgabe 5/2023

Medical Oncology 5/2023 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.